Commonwealth of Pennsylvania Public School Empls Retrmt SYS Takes $134,000 Position in Silence Therapeutics plc (NASDAQ:SLN)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Silence Therapeutics plc (NASDAQ:SLN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 19,467 shares of the company’s stock, valued at approximately $134,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS owned approximately 0.07% of Silence Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Eventide Asset Management LLC bought a new position in shares of Silence Therapeutics during the third quarter valued at $11,635,000. Parkman Healthcare Partners LLC increased its position in shares of Silence Therapeutics by 71.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock worth $9,051,000 after purchasing an additional 208,029 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in Silence Therapeutics by 219.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after purchasing an additional 321,300 shares during the last quarter. Janus Henderson Group PLC boosted its position in Silence Therapeutics by 32.8% in the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after buying an additional 268,250 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in Silence Therapeutics in the third quarter valued at about $207,000. Institutional investors own 98.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SLN. Chardan Capital reiterated a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Morgan Stanley cut their price objective on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th. The Goldman Sachs Group cut their price target on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a report on Tuesday, March 4th. Finally, BMO Capital Markets decreased their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Silence Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Trading Up 11.1 %

Shares of NASDAQ:SLN opened at $3.69 on Friday. Silence Therapeutics plc has a 1-year low of $3.19 and a 1-year high of $24.38. The stock has a market capitalization of $110.44 million, a P/E ratio of -2.35 and a beta of 1.08. The business has a 50-day moving average price of $4.68 and a two-hundred day moving average price of $10.02.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.